Navigation Links
Sagent Pharmaceuticals Inc. Completes $53 Million Series A Financing
Date:9/27/2007

SCHAUMBURG, Ill., Sept. 27 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company today announced the closing of a $53 million Series A financing led by Vivo Ventures. Proceeds from the financing will be used primarily to fund near-term product launches, product development activities and strategic business initiatives, including numerous development, sales and marketing, manufacturing and distribution partnerships.

"We appreciate Vivo Ventures' continued commitment to Sagent's long-term growth," said Jeffrey M. Yordon, CEO, founder and chairman of the board of Sagent Pharmaceuticals. "This venture funding enables us to quickly advance many of our recent development efforts into near-term commercialization while accelerating development of our extensive pipeline. We are confident that our strong financial position and experienced management team, combined with the extensive experience and capabilities of our business partners, positions us to achieve rapid success in our target specialty product market."

About Sagent Pharmaceuticals, Inc.

Sagent Pharmaceuticals, founded in 2006, is a privately held specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific focus on injectable products. Sagent has created a unique, global network of resources, comprised of rapid development capabilities, sophisticated manufacturing and innovative drug-delivery technologies, quickly yielding an extensive portfolio of pharmaceutical products that fulfills the evolving needs of patients. Sagent currently has more than 200 products in development.

For more information about the company and its products, please visit http://www.sagentpharma.com.

About Vivo Ventures

Vivo Ventures is a life-sciences focused venture capital firm with more than $650 million under management. Vivo
'/>"/>

SOURCE Sagent Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Supply of Radiopharmaceuticals Hampered by Attacks
2. FDA approves Watson Pharmaceuticals Oxytrol patch
3. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
4. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
5. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
6. Top Pharmaceuticals Influence Doctors Prescriptions
7. More Study On Side Effects of ADHD Drug Needed: Shire Pharmaceuticals
8. Personalized Medicine and Innovative Pharmaceuticals
9. New lease of life for asthmatics by Accentia Biopharmaceuticals
10. Pravastatin Launched by Watson Pharmaceuticals
11. Tata Industries picks up stake in Indigene Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... parents should leave prenatal picture-taking to medical professionals, the ... ultrasound imaging and heartbeat monitors to get "keepsake" images ... "Although there is a lack of evidence ... monitors, prudent use of these devices by trained health ... engineer, said in an agency news release. "Ultrasound ...
(Date:12/17/2014)... Kathleen Doheny HealthDay ... Chronic sleep loss is rampant in America, and work commitment ... is the No. 1 sleep killer," said Dr. Mathias Basner, ... the University of Pennsylvania Perelman School of Medicine. A ... older, found that work is the main activity exchanged for ...
(Date:12/15/2014)... Palm Beach, FL (PRWEB) December 15, 2014 ... Care , knows that holidays can be a daze of ... From slips and falls while decking halls, to burns when ... plenty of holiday hazards that can happen at any time. ... for pain, MD Now has made a list of helpful ...
(Date:12/15/2014)... 2014 (HealthDay News) -- Expert pilots process visual information ... they make better decisions during landings, a new study ... techniques for pilots to master, and 36 percent of ... occur during final approach and landing. Researchers monitored ... moderately experienced pilots while they were at the controls ...
(Date:12/15/2014)... December 15, 2014 At the leading, ... AutismOne and Focus Autism will ... with research on the effects of toxins to children’s ... intervention information. , Luminaries such as Dr. Lucija ... abroad with esteemed, credentialed colleagues of the United States ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... , The inactivity or "silence" of certain genes ... leukemia as well as in response to treatment, according to ... specialists from the University Hospital of Navarra and the Center ... as well as the Reina Sofa Hospital in Cordoba, Andalusia. ...
... Company, the nation,s leading builder of healthcare facilities, has ... with the $42 million Phase Two expansion to the ... in March 2009 with completion scheduled for March 2011. ... emergency rooms, ICU, CCU, three operating rooms and 26 ...
... Link as SCHIP Legislation Signed Into LawWASHINGTON, Feb. ... voice for more than 36,000 frontline providers of ... commended President Barack Obama for singling out the ... signed an historic expansion of the State Children,s ...
... missed key DNA variant, researchers say , , FRIDAY, Feb. ... DNA called copy number variants may play a role ... findings support a sharp change of direction in genetics ... decades, researchers have identified dozens of genes and single ...
... ,History Shows Avalon Is No Champion of Corporate Governance,TUCSON, ... PRSC ) today commented on the recent ... Inc. (Pink Sheets: CITY) together with other related persons, ... sole director of Avalon, intends to initiate a consent ...
... Feb. 6 ev3 Inc. (Nasdaq: EVVV ) ... and its financial guidance for 2009 on Tuesday, Febuary 24, ... conference call and webcast the same day at 7:30 a.m. ... review its fourth quarter and full-year operating results and future ...
Cached Medicine News:Health News:New genes involved in acute lymphoblastic leukemia play fundamental role in prognosis of the disease 2Health News:Turner to Manage Construction of $42 Million Expansion of Northern Inyo Hospital in Bishop, Calif. 2Health News:Doctors of Optometry Cheer Obama's Call to Action on Children's Vision 2Health News:Doctors of Optometry Cheer Obama's Call to Action on Children's Vision 3Health News:Genome Study Points to New Culprit for Schizophrenia 2Health News:Providence Service Corporation Comments on Consent Solicitation by Avalon Correctional Services, Inc. 2Health News:Providence Service Corporation Comments on Consent Solicitation by Avalon Correctional Services, Inc. 3Health News:Providence Service Corporation Comments on Consent Solicitation by Avalon Correctional Services, Inc. 4Health News:Providence Service Corporation Comments on Consent Solicitation by Avalon Correctional Services, Inc. 5Health News:Providence Service Corporation Comments on Consent Solicitation by Avalon Correctional Services, Inc. 6Health News:Providence Service Corporation Comments on Consent Solicitation by Avalon Correctional Services, Inc. 7Health News:ev3 Inc. to Report 2008 Fourth Quarter and Full-Year Financial Results and Host Conference Call on February 24, 2009 2
(Date:12/17/2014)... NASHVILLE, Tenn. , Dec. 17, 2014  Strategic ... health management software solutions, today announced a strategic agreement ... the New Jersey regional marketplace.  ... and enhance the health and wellness solutions QualCare brings ... and the surrounding region. QualCare ...
(Date:12/17/2014)... ANGELES , Dec. 17, 2014  ImmunoCellular ... the US Patent and Trademark Office (USPTO) has ... ICT-107, a dendritic cell-based immunotherapeutic vaccine targeting six ... The claims of US Patent No. 8,871,211, which ... neural cancer by administering a dendritic cell composition ...
(Date:12/15/2014)... LONDON , December 15, 2014 /PRNewswire/ ... Am 19. und 20. Februar ... das Aegate SAFE MEDICINE ECOSYSTEM PARTNER PROGRAMM ... zu besuchen. Diese Tagung ... Gemeinschaft die Möglichkeit geben, die neue profitablen ...
Breaking Medicine Technology:Strategic Health Services to collaborate with QualCare on Population Health and Wellness Technology for QualCare Members 2Strategic Health Services to collaborate with QualCare on Population Health and Wellness Technology for QualCare Members 3ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2Symposium über Aegates Ecosystem-Partner-Programm für sichere Medikamente vom 19. - 20. Februar 2015 in Amsterdam 2
... Switzerland, September 15, 2010 ... ... var ... by longUrl, so we need to grab the first one. for (var r in data.results) { first_result ...
... 14 ThermoGenesis Corp. (Nasdaq: KOOLD ), a ... store adult stem cells, said today that revenues for the ... of $4.0 million for the same quarter a year ago. ... million. The Company recorded disposable revenues of $4.8 ...
Cached Medicine Technology:ProstateHealthIndex.org Website Offers Latest on Assessing Prostate Cancer Risk 2ProstateHealthIndex.org Website Offers Latest on Assessing Prostate Cancer Risk 3ProstateHealthIndex.org Website Offers Latest on Assessing Prostate Cancer Risk 4ProstateHealthIndex.org Website Offers Latest on Assessing Prostate Cancer Risk 5ProstateHealthIndex.org Website Offers Latest on Assessing Prostate Cancer Risk 6ProstateHealthIndex.org Website Offers Latest on Assessing Prostate Cancer Risk 7ThermoGenesis Announces Fourth Quarter Revenues of $7.2 Million; Reduces Net Loss to $171,000 2ThermoGenesis Announces Fourth Quarter Revenues of $7.2 Million; Reduces Net Loss to $171,000 3ThermoGenesis Announces Fourth Quarter Revenues of $7.2 Million; Reduces Net Loss to $171,000 4ThermoGenesis Announces Fourth Quarter Revenues of $7.2 Million; Reduces Net Loss to $171,000 5ThermoGenesis Announces Fourth Quarter Revenues of $7.2 Million; Reduces Net Loss to $171,000 6ThermoGenesis Announces Fourth Quarter Revenues of $7.2 Million; Reduces Net Loss to $171,000 7
Rheumatoid factor calibrator (Latex enhancedimmunoturbidimetric)...
Fructosamine Calibrator...
CRP high sensitivity calibrator series...
CRP Calibrator...
Medicine Products: